(2S)-氨基-4-[(叔丁氧羰基)氨基]丁酸 | 10270-94-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S)-氨基-4-[(叔丁氧羰基)氨基]丁酸
• 中文别名: N'-叔丁氧羰基-L-2,4-二氨基丁酸
• 英文名称: 4--L-2,4-diaminobutyric acid
• 英文别名: N^g-(tert-butyloxycarbonyl)-L-2,4-diaminobutyric acid；(2S)-2-amino-4-[(tert-butoxycarbonyl)amino]butanoic acid；(S)-2-amino-4-((tert-butoxycarbonyl)amino)butanoic acid；H-Dab(Boc)-OH；N-γ-(tert-butoxycarbonyl)-L-diaminobutyric acid；N(γ)-tert. Butyloxycarbonyl-L-α,γ-diamino-buttersaeure；(2S)-2-amino-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• CAS: 10270-94-7
• 化学式: C₉H₁₈N₂O₄
• 分子量: 218.253
• InChiKey: ICJFZQLAIOCZNG-LURJTMIESA-N

物化性质

• 熔点：
  216℃
• 沸点：
  388.2±37.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在室温、密闭且干燥的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Dab(boc)-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Dab(boc)-oh
CAS number: 10270-94-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H18N2O4
Molecular weight: 218.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2S)-氨基-4-[(叔丁氧羰基)氨基]丁酸 在 palladium on activated charcoal 氨 、 氢气 、 sodium carbonate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成
  参考文献：
  名称：

  含N（ω）-硝基精氨酸的二肽酰胺。神经元一氧化氮合酶的有效抑制剂和高选择性抑制剂。

  摘要：

  选择性抑制一氧化氮合酶（NOS）的同工型在治疗某些因一氧化氮（NO）过量生产而引起的疾病中可能有用。最近，我们报道了二肽甲酯D-Phe-D-Arg（NO）（）2-OMe（19）作为nNOS的适度抑制剂（K（i）= 2 microM），但对iNOS的选择性为高达1800倍（Silverman，RB; Huang，H .; Marletta，MA; Martasek，PJ Med.Chem。1997，40，2813-2817）。这里合成了包含硝基精氨酸和Phe以外的氨基酸的152种二肽酰胺的文库，并筛选了其活性。含有碱性胺侧链（20-24）的二肽酰胺可实现对nNOS优于eNOS和iNOS的出色抑制力和选择性。这表明在酶活性位点可能发生静电（或氢键）相互作用。在这些化合物中，最有效的nNOS抑制剂是L-Arg（NO）（）2-L-Dbu-NH（2）（23）（K（i）= 130 nM），它对eNOS的选择性也最高（>

  DOI：

  10.1021/jm990111c
• 作为产物：
  描述：

  N-重氮基氨基甲酸叔-丁基酯 在 sodium hydroxide 、 氨 、 calcium 作用下， 生成 (2S)-氨基-4-[(叔丁氧羰基)氨基]丁酸
  参考文献：
  名称：

  Poduska,K., Collection of Czechoslovak Chemical Communications, 1966, vol. 31, p. 2955 - 2972

  摘要：

  DOI：

文献信息

• [EN] MACROCYLIC PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE MACROCYCLIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015150557A1

  公开（公告）日：2015-10-08

  The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的取代大环嘧啶衍生物，其中变量的含义如权利要求中所定义。根据本发明的化合物具有EF2K抑制活性，还可能具有Vps34抑制活性。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• Methotrexate analogs. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogs containing a basic amino acid side chain
  作者：Andre Rosowsky、James H. Freisheim、Richard G. Moran、Vishnu C. Solan、Henry Bader、Joel E. Wright、Mary Radike-Smith

  DOI：10.1021/jm00155a012

  日期：1986.5

  Analogues of the antitumor antifolate methotrexate (MTX) were synthesized in which the glutamate (Glu) moiety was replaced by ornithine (Orn), 2,4-diaminobutyric acid (Dab), or 2,3-diaminopropionic acid (Dap). An aminopterin (AMT) analogue with Orn in place of Glu was also synthesized. The MTX analogues were obtained by reaction of 4-amino-4-deoxy-N10-methylpteroic acid (mAPA) and N omega-Boc-alpha

  合成了抗肿瘤抗叶酸甲氨蝶呤（MTX）的类似物，其中谷氨酸（Glu）部分被鸟氨酸（Orn），2,4-二氨基丁酸（Dab）或2,3-二氨基丙酸（Dap）代替。还合成了以Orn代替Glu的氨基蝶呤（AMT）类似物。MTX类似物是通过在氨基氰基磷酸二乙酯存在下，使4-氨基-4-脱氧-N10-甲基蝶酸（mAPA）与N-ω-Boc-α，ω-二氨基链烷酸反应，然后用三氟乙酸（TFA）脱保护而获得的。 ）或通过对硝基苯基-mAPA与Nω-Boc-α，ω-二氨基链烷酸反应并随后用TFA处理。AMT类似物（APA-Orn）是通过在55°C下于55°C下使对硝基苯基4-氨基-4-脱氧-N10-甲酰基蝶酸酯与甲硅烷基化的Nδ-Boc-L-鸟氨酸反应3天（产率为45％） ），皂化（83％）和TFA裂解（89％）。APA-Orn是来自L1210小鼠白血病的二氢叶酸还原酶（DHFR）（IC50 = 0.072 micr
• [EN] CXCR3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR CXCR3
  申请人：CELGENE INT II SARL

  公开号：WO2018045246A1

  公开（公告）日：2018-03-08

  Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

  提供具有以下式I结构的化合物：其中R、R1、R2、R3a和R3b如本文所述定义。还提供了包含这些化合物的药物组合物，以及与它们的制造和使用相关的方法。
• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。
• COMPOUNDS
  申请人：Enterprise Therapeutics Limited

  公开号：US20210188855A1

  公开（公告）日：2021-06-24

  Compounds of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.

  通式（I）中R1、R2、R3、R4和X的化合物是上皮钠通道（ENaC）的抑制剂，可用于治疗或预防呼吸道疾病和状况、皮肤状况和眼部状况。